Latest news with #MediaOutReachNewswire
Arabian Post
a day ago
- Health
- Arabian Post
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least one related health condition. The once-weekly injectable supports weight loss when used alongside a reduced-calorie diet and increased physical activity. The launch marks a step toward evidence-based, compassionate treatment of obesity as a chronic disease—not a personal failing. SINGAPORE – Media OutReach Newswire – 12 July 2025 – A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore. Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health. The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes. ADVERTISEMENT The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2–4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription. Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity' Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management. Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.' References: Wegovy Singapore Prescribing Information, February 2025 Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. World Obesity. Retrieved from World Obesity. Retrieved from Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at World Health Organization. (2024). Obesity and As accessed on 22nd May 2025. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees. For more information, visit
The Sun
a day ago
- Health
- The Sun
Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious chronic diseases, has announced the availability of Wegovy® (semaglutide 2.4mg) in Singapore. Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health. The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes. The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2-4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription. Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity' Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management. Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.' References: 1. Wegovy Singapore Prescribing Information, February 2025 2. Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508. 3. World Obesity. Retrieved from 4. World Obesity. Retrieved from 5. Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at 6. World Health Organization. (2024). Obesity and As accessed on 22nd May 2025. 7. Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. Hashtag: #NovoNordisk #Wegovy The issuer is solely responsible for the content of this announcement.
The Sun
a day ago
- Entertainment
- The Sun
'Eternal City' Pompeii Exhibition Opens in Hunan, Marking New Sino-Italian Cultural Exchange
CHANGSHA, CHINA - Media OutReach Newswire - 11 July 2025 - On July 8, the exhibition 'Encountering Pompeii: The Eternal City' opened at the Hunan Museum's Special Exhibition Hall 1. It is jointly organized by the Hunan Museum, Naples National Archaeological Museum, Archaeological Museum of the Campi Flegrei in the Castle of Baia, and the Collections Department of Naples University 'Federico II,' with Beijing Shengxuan Cultural Group Co., Ltd. as co-organizer. Duan Xiaoming, Director of the Hunan Museum, noted in his opening speech that this year marks the 55th anniversary of China-Italy diplomatic ties. This exhibition continues the museum's collaboration with Italian cultural institutions, following the 'The Trans-Cultural Exchanges and Interactions Between Italy and China From the 13th Century to 16th Century' (2017), 'Ancient Egyptian Finds Exhibition' (2018), and 'She Walks in Beauty: Women of the Han Dynasty and Roman Empire' (2024), showcasing close cooperation in heritage preservation and exchange. The exhibition highlights the ancient Roman city of Pompeii, buried and preserved by Mount Vesuvius' eruption in 79 CE. Once a thriving Mediterranean trade hub, Pompeii was first settled by the Oscans in the 8th century BCE, later allied with Greek city-states, and became a flourishing Roman metropolis. UNESCO calls it 'the only archaeological site offering a complete picture of an ancient Roman city.' More than 130 original Italian artifacts—many debuting in Hunan or even China—are on display, including frescoes, sculptures, bronzes, and gold. Paired with recreated scenes, they vividly portray Pompeii's grandeur, daily life, and artistic culture. The exhibition comprises four sections: 'Lost Civilization: A City Frozen in Time'; 'The Best Place on Earth: Pompeii and Its Surroundings'; 'Stories of the Ancient City: Lives of Pompeiians'; and 'The Tragedy of the Volcano: Eternal Awe and Love.' A concluding immersive space with multi-channel projections and 3D effects lets visitors experience Pompeii and reflect on life's fragility amid disaster. On opening day, the museum also hosted a live dubbing performance and an academic lecture by Italian experts. The exhibition runs through November 2.
The Sun
a day ago
- Health
- The Sun
HKCSS Fosters Cross-Sector Collaboration and Adoption of Gerontechnology to Formulate Hong Kong Dementia Care Action Plan
HONG KONG SAR - Media OutReach Newswire - 11 July 2025 - The Hong Kong Council of Social Service (HKCSS) is actively promoting support services for dementia and is leveraging gerontechnology to provide comprehensive support for patients and their caregivers. Through cross-sector collaboration, continuous innovation and extensive consultation, HKCSS is taking forwards the formulation of the 'Hong Kong Dementia Care Action Plan' (Action Plan) and launches a series of exchange and consultation programmes in the field of social service, health and innovative technologies to encourage society to rethink the direction of dementia service development in response to the challenges posed by an ageing population. The Action Plan is expected to be officially published in 2026. HKCSS rolls out the formulation of the Action Plan in two phases. The formulation of the Action Plan by HKCSS comprises two stages. In the first stage, the focus is on developing a framework and gathering stakeholder opinion through various channels. In July, a 'Dementia and Care Planning Seminar' is held to discuss the current care plan arrangements and limitations for people with dementia, as well as the future development of carer support services. Between September and November in 2025, several events focusing on agenda discussion will take place in conjunction with 'World Alzheimer's Day' in September and the 'Gerontech and Innovation Expo cum Summit' in November. Public consultation will be conducted in the second stage to finalise the Action Plan. According to the World Health Organization, there were 57 million people worldwide living with dementia in 2021. To address the challenges dementia poses to public health and society, countries worldwide are formulating or updating dementia strategies. Ms Grace Chan, Chief Executive of HKCSS, states that 'There are approximately over 100,000 dementia patients in Hong Kong. HKCSS hopes to connect international and local stakeholders through various programmes to share experiences and strengthen cross-regional and cross-sector collaboration in promoting the development of dementia care and social services, effectively supporting patients and their caregivers in an ageing society.' This year, in March, HKCSS organised an international symposium titled 'Charting the Future: A Strategic Action Plan for Dementia Care', facilitating close exchanges and discussions with local and overseas stakeholders on various aspects related to dementia. A number of international and local experts shared insights covering research, prevention, living support, policy and social service practices. Mr Greg Shaw, Former Director of International and Corporate Relations at the International Federation on Ageing (IFA), highlighted the importance of 'people-oriented' integrated care model through technology, to develop a dementia-inclusive society in the long run. Promoting the idea that 'prevention is better than cure' is equally important. Research from the Chinese University of Hong Kong's Department of Otorhinolaryngology, Head and Neck Surgery found a positive relationship between maintaining hearing and preventing dementia, advising the elderly to wear appropriate hearing aids to timely improve and slow cognitive decline. Additionally, local organisations, in collaboration with the Hong Kong University of Science and Technology, are implementing the 'Caring Communities for Dementia Campaign', using IoT technology to quickly locate missing persons. This initiative allows individuals with dementia to participate actively and safely in the community, alleviating caregivers' concerns about the risk of wandering. Another focus of the symposium was the discussion of the Action Plan. Ms Katie Wong, Chief Officer (Elderly Service) of HKCSS, and Ms Karrie Chan, Deputy Director (Elderly, Rehabilitation & Community) of Hong Kong Christian Service, along with the members of Specialized Committee on Elderly Service, shared the current status of dementia development in Hong Kong. They proposed that prevention, early diagnosis, and early intervention are key strategies for the future development of dementia services, and engaged with participants from social services, academia and institutions to discuss local conditions and suggested directions. Several technology companies demonstrated gerontechnology solutions applicable to dementia care on-site. In addition, during the 'S+ Summit cum Expo' in May, a thematic discussion on 'Co-Creating Dementia-Friendly Communities: A Journey of Inclusion and Collaboration' explored multi-faceted cooperation through social service, business, and urban planning to enhance facilities and services for the elderly in preventing dementia and making life more convenient for dementia patients and their caregivers. HKCSS aims to harness the social power through cross-sector collaboration and innovation to promote the formulation of dementia care strategies, jointly building a dementia-friendly environment and sustainable community.
The Sun
a day ago
- Business
- The Sun
SIBUR develops new polyethylene grade for blown films
MOSCOW, RUSSIA - Media OutReach Newswire - 11 July 2025 - SIBUR, the largest producer of polymers and synthetic rubbers in Russia, has developed a new grade of linear low-density polyethylene (LLDPE) designed specifically to produce blown films, which are in high demand in the Turkish market. In the blown film manufacturing process, melted polyethylene is inflated with air into a bubble, then cooled and rolled into a reel. This technology allows the production of films with excellent durability and elasticity as well as films of varying thicknesses. Blown film is widely used in food packaging and agriculture. The new grade of LLDPE marks another step in strengthening SIBUR's position in the global flexible packaging market. The product has successfully passed approval tests with key film producers in Turkey and is ready for large-scale supply. Russian processing partners will also be able to supply finished films made from SIBUR's feedstock to the Turkish market. The LLDPE grade developed by SIBUR contains slip and antiblock additives, which reduce friction and prevent the blocking of film layers in rolls. This enables high-speed packaging operations and ensures the stability of film rolls during storage and transportation. The new grade with additives eliminates the need for customers to purchase extra modifiers and masterbatches, making the technological process for polymer processors and film manufacturers much simpler and reducing their overall costs.
